IVUS + NIRS: The PROSPECT II Study Published on The Lancet

11 March 2021

The PROSPECT II Study has been published in the current issue of The Lancet.


Study findings show that combined #NIRS and #IVUS detects angiographically non-obstructive lesions with a high lipid content and large plaque burden that are at increased risk for future adverse cardiac outcomes.


Click  The PROSPECT II Study to read more


Latest News:

Gender matter! EUKON move on mission 5

Caserta, ITALY – August 8th, 2023   We are absolutely…

Read More >

EUKON FT1000 ranking 2022 on Financial Times

FT 1000: the sixth annual list of Europe’s fastest-growing companies…

Read More >

EUKON Leader della Crescita 2022

Leader della Crescita is  rank of first 450 companies, done…

Read More >